Please login to the form below
Learning to invest in doctors’ education
Pharmaceutical companies know doctors want high-value educational content. In a highly pressurised, cost-constrained healthcare environment with increasing demands for value and improved patient outcomes, time-poor doctors are calling out for more educational resources. However, the industry can find it hard to make a break from traditional methods of engaging with doctors, such as promotional communications and the traditional sales representative call to hospitals and GP surgeries.
This whitepaper explores exclusive new research highlighting the importance of educational and non-promotional clinical content to doctors, demonstrating why it should play an important part in any pharma engagement strategy.
By showing a commitment to doctors’ education, pharma companies make their interactions with these doctors more powerful, increasing the chances of long-term advocacy. This mutually beneficial approach meets the needs of both the company and the doctor.
There remains an important place for branded, promotional content and this whitepaper discusses how to balance the provision of promotional and nonpromotional content to create lasting, positive relationships with doctors. This not only helps fill gaps in their medical education but can build trust in the industry and ultimately improve patient care and outcomes.
The industry is well-used to taking a long-term approach to drug development cycles, therapy area endeavours and drug patent lifecycles. It’s time to be comfortable looking beyond the short-term for doctors’ education, too.
To read the full report please click here.
Company Details
M3 (EU)
Address:
101 Park Drive
Milton Park
Milton Park
Abingdon
Oxfordshire
OX14 4RY
UK
Latest content on this profile
- Learning to invest in doctors’ education
- Pharmaceutical companies know doctors want high-value educational content. In a highly pressurised, cost-constrained healthcare environment with increasing demands for value and improved patient outcomes, time-poor doctors are calling out for more educational resources. However, the industry can find it hard to make a break from traditional methods of engaging with doctors, such as promotional communications and the traditional sales representative call to hospitals and GP surgeries.
M3 (EU)
- Engaging doctors around the globe
- Embedding a digital strategy as a prominent part of a pharmaceutical marketing campaign is becoming ever more important. Despite some perceived reluctance on the part of the industry, pharmaceutical companies are now exploring and exploiting a myriad of different digital channels in order to deliver content to, and engage with, their target audiences.
M3 (EU)
- How do doctors spend their time online?
- In our recent research piece, Doctor networks: The rules of engagement for pharma, some overarching principles for online engagement between the pharmaceutical industry and doctors were defined.
M3 (EU)
- How do doctors want to engage with pharma on new products?
- More than 80% of European doctors agree they are interested in staying up-to-date with new developments about pharmaceutical products. But what influences their choice of treatment and how do they prefer to receive product information?
M3 (EU)
- M3 Acquires MirVracha LCC in Russia Launching Full-Scale Development of Physician Platform Business in Russia
- M3, Inc. (Headquarters: Tokyo, Japan; CEO: Itaru Tanimura; URL: https://corporate.m3.com/; “M3” below) has announced the acquisition of MirVracha LCC (Headquarters: Moscow, Russia; CEO: Shotaro Yamamoto; “MirVracha” below), a website provider for healthcare professionals in Russia. M3 operates m3.com, a specialized web portal for medical professionals that delivers healthcare related information to its 300,000+ physician members in Japan. Presence outside of Japan includes the U.S., U.K., France, China, Korea and India, with aggressive business expansion overseas that has amassed over 6 million physicians as members across its global platforms. This allows provision of services including marketing support, marketing research, and job placement support that leverage the platform’s powerful value as a media channel. MirVracha operates the medical professional website "МирВрача" with over 400,000 medical professional members, equivalent to roughly 60% of all physicians in Russia, and mainly provides marketing support services for pharmaceutical companies. Since its founding by Shotaro Yamamoto in 2011, MirVracha has focused on building a quality network of healthcare professionals as well as improving content creation capabilities, and is now utilized by major Russian pharmaceutical companies to provide drug and disease information. In 2012, M3 entered into a capital and business alliance that includes the licensing of the MR-kun service, and have since developed a strong relationship with MirVracha through provision of support and know-how surrounding business launches and operations. M3 has completed the acquisition of MirVracha as a subsidiary, and will leverage its experience and know-how gained through its overseas business development in the United States, Europe, Asia, and other regions. M3 will move forward with the full-scale development of services related to its physician platform in Russia by combining the high-quality network of physicians, medical institutions, and pharmaceutical companies that MirVracha has cultivated in Russia, with M3's expertise in operating websites and various services for healthcare professionals.
M3 (EU)
- Revolutionising the Digital Content Delivery Model
- Pharmaceutical industry processes don’t have to make the delivery of marketing campaigns slow and unmanageable, and thus ineffective. Changing working practices and really, truly thinking differently about how to deliver materials in a new and faster way is possible, but only if companies are ready to consider and embrace new, novel ways of working. Utilising these methods, M3 reduced a client's delivery time from 75 days to just 7.5 days
M3 (EU)
